Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seagen Inc (NQ: SGEN )

213.70 +7.31 (+3.54%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Seagen Inc

< Previous 1 2 3 4 Next >
Seagen to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
From Seagen Inc.
Via Business Wire
Seagen Statement on Outcome of Daiichi Sankyo Arbitration
From Seagen Inc.
Via Business Wire
Seagen Reports Second Quarter 2022 Financial Results
From Seagen Inc.
Via Business Wire
Seagen and Astellas Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer
From Seagen Inc.
Via Business Wire
Seagen to Host Conference Call and Webcast Discussion of Second Quarter 2022 Financial Results on July 28, 2022
From Seagen Inc.
Via Business Wire
Seagen Announces Results from Pivotal MOUNTAINEER Trial Demonstrating Clinically Meaningful Antitumor Activity of TUKYSA® (tucatinib) in Combination with Trastuzumab in Previously Treated HER2-Positive Metastatic Colorectal Cancer
From Seagen Inc.
Via Business Wire
Seagen and Genmab Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
From Seagen Inc.
Via Business Wire
Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
From Genmab A/S
Via Business Wire
ADCETRIS® (brentuximab vedotin) Plus Standard of Care Chemotherapy Demonstrates Superior Event-Free Survival (EFS) vs. Standard of Care Alone in Children and Young Adults with Previously Untreated High-Risk Hodgkin Lymphoma
From Seagen Inc.
Via Business Wire
Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma
From Takeda Pharmaceutical Company Limited
Via Business Wire
Seagen Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA® (tucatinib) in Combination With Trastuzumab in HER2-Positive Metastatic Colorectal Cancer
From Seagen Inc.
Via Business Wire
Seagen Announces Resignation of President, Chairman & CEO Clay Siegall
From Seagen Inc.
Via Business Wire
Seagen President, CEO and Chairman Clay Siegall Takes Leave of Absence
From Seagen Inc.
Via Business Wire
Seagen Reports First Quarter 2022 Financial Results
From Seagen Inc.
Via Business Wire
Seagen to Highlight Data from Expanding Oncology Portfolio at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
From Seagen Inc.
Via Business Wire
Seagen Announces Plans to Expand Pacific Northwest Biomanufacturing Capacity to Support Growing Portfolio of Transformative Cancer Medicines
From Seagen Inc.
Via Business Wire
European Commission Approves PADCEV™ (enfortumab vedotin) for Locally Advanced or Metastatic Urothelial Cancer
From Seagen Inc.
Via Business Wire
Seagen Announces Jury Award in Patent Infringement Case Against Daiichi Sankyo
From Seagen Inc.
Via Business Wire
Seagen to Highlight Preclinical Data for Enfortumab Vedotin and Two Novel Antibody-Drug Conjugates at AACR Annual Meeting
From Seagen Inc.
Via Business Wire
Seagen to Host Conference Call and Webcast Discussion of First Quarter 2022 Financial Results on April 28, 2022
From Seagen Inc.
Via Business Wire
Seagen and Sanofi Announce Collaboration to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates
From Seagen Inc.
Via Business Wire
Astellas and Seagen Announce CHMP Confirms Positive Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
From Seagen Inc.
Via Business Wire
Seagen and Genmab Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
From Seagen Inc.
Via Business Wire
Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
From Genmab A/S
Via Business Wire
Seagen and Astellas Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy
From Seagen Inc.
Via Business Wire
Seagen Reports Fourth Quarter and Full Year 2021 Financial Results
From Seagen Inc.
Via Business Wire
Seagen to Present at the 11th Annual SVB Leerink Global Healthcare Conference
From Seagen Inc.
Via Business Wire
ADCETRIS® Combination Significantly Improves Overall Survival in Newly Diagnosed Patients with Advanced Hodgkin Lymphoma
From Seagen Inc.
Via Business Wire
Groundbreaking Clinical Trials Accelerating New Treatment Options for Pancreatic Cancer
Palm Beach, FL – February 2, 2022 – FinancialNewsMedia.com News Commentary – In the battle against pancreatic cancer, new and innovative clinical trials have become extremely critical. These trials... 
Via FinancialNewsMedia
Seagen Appoints Lee Heeson as Executive Vice President, Commercial International
From Seagen Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.